Nanocosmetics: benefits and risks

Various nanomaterials/nanoparticles (NPs) have been used for the development of cosmetic products - a field so-called nanocosmetic formulations. These advanced materials offer some benefits, while their utilization in the cosmetic formulations may be associated with some risks. The main aim of this editorial is to highlight the benefits and risks of the nanomaterials used in the cosmetic products

ANALYTICAL METHOD VALIDATION, PHARMACOKINETICS AND BIOEQUIVALENCE STUDY OF DIMETHYL FUMARATE IN HEALTHY IRANIAN VOLUNTEERS

Objective: Pharmacokinetic evaluation of Dimethyl Fumarate (DMF) in the Iranian population wasn’t studied. So, the aim of this research is the validation of the analytical method and evaluation of the pharmacokinetic properties and bioequivalence of the generic form of this drug versus the reference product. Methods: 2 single-dose, test, and reference DMF products were orally administered to 24 healthy volunteers. The washout period was 28 d between the treatments. Monomethyl fumarate as the metabolite of DMF was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the method was validated. Also, the pharmacokinetic parameters were calculated for bioequivalence evaluation. Results: The analytical method was validated and linear over the range of 31.25-4000 ng/ml (R2= 0.997). In addition, the method was precise and accurate in the low, medium, and high concentrations. The results indicated that the 2 products had similar pharmacokinetics. Further, the 90% CI of the mean ratios of the test versus the reference products of the log-transformed area under the concentration-time curve over 10 h (0.99 to 1.02) and peak concentration (0.98 to 1.03) were within the acceptable range of 0.8 to 1.25 and the generic product of DMF could be similar to that of the reference product. Conclusion: The applied analytical method is selective, accurate, precise, and repeatable for the analysis of monomethyl fumarate (MMF) in plasma. Also, the bioequivalence study showed no significant difference between the pharmacokinetic parameters of these 2 products. So, the DMF test product can be claimed to be bioequivalent with the reference product

Nano-suspension coating as a technique to modulate the drug release from controlled porosity osmotic pumps for a soluble agent

No description supplie

Efficacy of Furosemide 0.125 Percent topical gel and KOH 10 Percent topical solution in the treatment of patients with warts: a comparison study

Background. Warts are a common skin disease affecting individuals of all ages worldwide. This clinical trial aims to compare the effectiveness of furosemide 0.125 Percent topical gel and KOH 10 Percent topical gel in treating patients with warts. Methods. Patients diagnosed with warts by dermatologists were included in the study and treated with either 0.125 Percent furosemide or 10 Percent KOH for two months. Patients were examined and imaged at the beginning of the study and in weeks 4 and 8 to assess the number, diameter, and height of warts and complications. Results. The study included 40 patients (48 lesions) with common warts, with 20 patients in each intervention group. In the furosemide group, the average diameter of warts decreased from 4.25 ± 1.43 mm in the first visit to 4.14 ± 1.47 mm in the final visit. In contrast, the average diameter of warts in the KOH group decreased from 3.89 ± 1.67 mm to 3.02 ± 1.49 mm. No complications were reported in the furosemide group, whereas seven complications related to redness and burning were observed in the KOH group. Conclusion. Furosemide 0.125 Percent is effective and safe for treating skin warts. However, it is less effective than KOH in reducing the diameter and height of warts. This study's findings suggest that furosemide can be a promising alternative to KOH in treating warts, especially for patients with sensitive skin or those who experience complications with KOH treatment. Further research is needed to determine the optimal treatment duration and dosage of furosemide for treating warts. Practical Implications. We can find new ways to reduce complications in treating warts

The influence of feeding linoleic, gamma-linolenic and docosahexaenoic acid rich oils on rat brain tumor fatty acids composition and fatty acid binding protein 7 mRNA expression

<p>Abstract</p> <p>Background</p> <p>Experimental studies indicate that gamma linolenic acid (GLA) and docosahexaenoic acid (DHA) may inhibit glioma cells growth but effects of oral consumption of these fatty acids on brain tumor fatty acid composition have not been determined in vivo.</p> <p>Methods</p> <p>GLA oil (GLAO; 72% GLA), DHA oil (DHAO; 73% DHA) were fed to adult wistar rats (1 mL/rat/day) starting one week prior to C6 glioma cells implantation and continued for two weeks after implantation. Control group were fed same amount of high linoleic acid safflower oil (74–77% linoleic acid). Fatty acid composition of tumor samples was determined in a set of 8–12 animals in each group and serum fatty acid in 6 animals per each group. Gene expression of tumor fatty acid binding protein 7 (FABP7), epidermal growth factor receptor (EGFR), peroxisome proliferator activated receptor γ (PPAR-γ) and retinoid × receptor-α (RXR-α) were determined in a set of 18 animals per group.</p> <p>Results</p> <p>DHAO feeding increased EPA of brain tumors and decreased ratio of n-6/n-3 fatty acids. Serum levels of EPA were also increased in DHAO group. A similar trend in serum and tumor levels of DHA were observed in DHAO group but it did not achieve statistical significance. GLAO increased serum concentration of GLA but had no significant effect on tumor GLA or dihomo-gamma linolenic acid (DGLA) concentrations. Gene expression of FABP7 was up-regulated in tumors of DHAO group but no other significant effects were observed on EGFR, PPAR-γ or RXR-α expression, and expression of these genes in tumors of GLAO were not different from SFO group.</p> <p>Conclusion</p> <p>Dietary supplementation of DHA containing oil could be an effective way to increase levels of long chain n-3 fatty acids in brain tumors and this increase may be mediated partly by up-regulation of FABP7 expression.</p

Dynamics of foam flow in a rock fracture: Effects of aperture variation on apparent shear viscosity and bubble morphology

There has recently been renewed interest in understanding the physics of foam flow in permeable media. As for Newtonian flows in fractures, the heterogeneity of local apertures in natural fractures is expected to strongly impact the spatial distribution of foam flow. Although several experimental studies have been previously performed to study foam flow in fractured media, none of them has specifically addressed that impact for parallel flow in a realistic fracture geometry and its consequences for the foam’s in situ shear viscosity and bubble morphologies. To do so, a comprehensive series of single-phase experiments have been performed by injecting pre-generated foams with six different qualities at a constant flow rate through a replica of a Vosges sandstone fracture of well-characterized aperture map. These measurements were compared to measurements obtained in a Hele-Shaw (i.e., smooth) fracture of identical hydraulic aperture. The results show that fracture wall roughness strongly increases the foam’s apparent viscosity and shear rate. Moreover, foam bubbles traveling in regions of larger aperture exhibit larger velocity, size, a higher coarsening rate, and are subjected to a higher shear rate. This study also presents the first in situ measurement of foam bubbles velocities in fracture geometry, and provides hints towards measuring the in situ rheology of foam in a rough fracture from the velocity maps, for various imposed mean flow rates. These findings echo the necessity of considering fracture wall when predicting the pressure drop through the fracture and the effective viscosity, as well as in situ rheology, of the foam

Relationship between β-Thalassemia minor and Helicobacter pylori infection

Background: Until now, no study has been reported investigating the association between β-thalassemia minor and Helicobacter pylori (H. pylori) infection. This study was designed to compare H. pylori infection rate between β-thalassemia minor patients and healthy controls. Methods: A number of 100 β-thalassemia minor patients (50 males, 50 females) and 100 gender-matched healthy controls were prospectively recruited in this study in a period of 3 months. The study population consisted of the people who referred to a health center in Babol, North of Iran, for premarital counseling. H. pylori status was assessed by measuring the anti-H. pylori IgG antibodies using enzyme-linked immunosorbent assay. Demographic information and informed consent were collected from all participants. Results: The overall H. pylori infection rate was 43%. The infection was significantly more prevalent in thalassemia patients (53%) than in the controls (33%) in both univariate (OR=2.29, 95% CI: 1.3-4.06) and multivariable analyses (OR=2.05, 95% CI: 1.12-3.76). Age was the only significant factor which was positively correlated with the infection in β-thalassemia minor cases (OR=1.11, 95% CI: 1.02-1.2). Gender, blood groups, residency, and education level were not related to the infection. Conclusions: According to the results, it can be concluded that β-thalassemia minor patients are possibly more susceptible to H. pylori infection than healthy people. Further studies are needed to discover more about the exact mechanisms of increased susceptibility to H. pylori infection in β-thalassemia minor patients